Phase 2 Endometrial Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing and able to give written consent to participate.
• Women between 18 and 75 years of age.
• People whose doctors estimate they are likely to survive for at least 3 months.
• People who have been confirmed by laboratory testing (tissue or cell samples) to have squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma of the cervix, at an advanced stage (FIGO 2018 stage III–IVA).
• People for whom curative surgery is not an option, and who have not previously received any systemic cancer treatments (such as radiotherapy, chemotherapy, immunotherapy, or biological therapy) before starting the combined chemotherapy and radiation treatment (CCRT) in this trial.
• People with a good general health and activity level, as measured by a standard scale (ECOG score of 0 or 1), meaning they are either fully active or have only minor limitations in physical activity.
• People who have at least one measurable area of cancer that can be tracked during the trial.
• People whose blood test results show that major organs (such as the liver, kidneys, and bone marrow) are functioning adequately, based on tests done within 7 days before starting treatment.
• People who agree to use contraception as required by the trial protocol.
• People who are willing to follow the trial's visit schedule and rules throughout the study.

Who may not be able to join:

• People who have already received other cancer treatments before starting the CCRT phase of this trial.
• People whose cancer was found to have progressed (gotten worse) during CCRT treatment assessment.
• People who have previously received immune checkpoint inhibitors (such as anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies), immune checkpoint activating drugs, immune cell therapies, or any other treatment targeting the immune system's response to tumours.
• People whose cancer has spread to the brain.
• People who have previously had an allogeneic stem cell transplant or a solid organ transplant.
• People who have, or have previously had, a condition that causes the immune system not to work properly, whether inherited or developed over time.
• People with a known or suspected allergy to drugs similar to the study drug, or a history of allergic reactions to chimeric or humanised antibodies, fusion proteins, or any ingredients in the study drug.
• People who test positive for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb) along with active hepatitis B virus (HBV DNA), hepatitis C antibody (HCVAb), or HIV antibody (HIVAb).
• People who have received a live virus vaccine within 4 weeks before the planned start of trial treatment.
• People who have had a serious heart or blood vessel event within the 6 months before joining, such as a pulmonary embolism (blood clot in the lungs), heart attack, significant heart failure, or a moderate-to-severe irregular heart rhythm.
• People who have had a stroke within the 6 months before joining.
• People with an active infection that requires treatment with systemic (whole-body) medications.
• People with uncontrolled high blood pressure, uncontrolled diabetes, or certain lung conditions such as interstitial lung disease, non-infectious pneumonia, pulmonary fibrosis, or acute lung disease.
• People who have needed regular steroid treatment (above a certain dose) or other immune-suppressing medications within the 14 days before entering the trial.
• People who have had another cancer diagnosis within the past 5 years, with some exceptions such as certain treated skin cancers or early-stage cervical conditions that are considered fully cured (confirm with trial site).
• People who have any other medical condition, ongoing treatment, or abnormal test result that the treating doctor believes could interfere with the trial results or make participation unsafe.
• People who are pregnant or breastfeeding.
• People who the investigator believes are unable or unwilling to follow the trial's requirements.

Important: Always verify eligibility with the trial site directly before applying.